Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study-Reference-Cited by-同舟云学术

Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study

Published:2022-02-28 Issue:7 Volume:41 Page:2121-2128
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Liu Dongmei^ORCID,Zhou Binbin^ORCID,Li Zhen^ORCID,Zhang Zhuojun^ORCID,Dai Xiaojuan^ORCID,Ji Zongfei^ORCID,Chen Huiyong^ORCID,Sun Ying^ORCID,Jiang Lindi^ORCID

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s10067-022-06110-5.pdf

Reference18 articles.

1. Choi HK, Mount DB, Reginato AM (2005) Pathogenesis of gout. Ann Intern Med 143(7):499–516. https://doi.org/10.7326/0003-4819-143-7-200510040-00009

2. Hoque KM, Dixon EE, Lewis RM, Allan J, Gamble GD, Phipps-Green AJ, HalperinKuhns VL, Horne AM, Stamp LK, Merriman TR, Dalbeth N, Woodward OM (2020) The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. Nat Commun 11(1):2767. https://doi.org/10.1038/s41467-020-16525-w

3. Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, Doherty S, Duley L, Hatton R, Rees F, Stevenson M, Zhang W (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392(10156):1403–1412. https://doi.org/10.1016/S0140-6736(18)32158-5

4. Dehghan A, Köttgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, Boerwinkle E, Levy D, Hofman A, Astor BC, Benjamin EJ, van Duijn CM, Witteman JC, Coresh J, Fox CS (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372(9654):1953–1961. https://doi.org/10.1016/S0140-6736(08)61343-4

5. Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, Yamanashi Y, Kasuga H, Nakashima H, Nakamura T, Takada Y, Kawamura Y, Inoue H, Okada C, Utsumi Y, Ikebuchi Y, Ito K, Nakamura M, Shinohara Y, Hosoyamada M, Sakurai Y, Shinomiya N, Hosoya T, Suzuki H (2012) Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3(764). https://doi.org/10.1038/ncomms1756

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of clinical and economic evaluation between selected generic and original febuxostat tablets in Chinese gout patients with hyperuricemia: A real-world multicenter retrospective study;Medicine;2024-01-26

2. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout;Expert Opinion on Drug Metabolism & Toxicology;2023-11-25